B+
Bull case
25%
Probability
Target price
$1.20
+145.4% vs current
CTSO
CytoSorbentsANasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$0.75
+53.4% vs current
B-
Bear case
25%
Probability
Target price
$0.35
-28.4% vs current
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Sentiment remains cautious-monitoring rather than post-earnings constructive. The main new finding is that the scheduled T3 earnings follow-up is date-misaligned: as of May 8, 2026, CytoSorbents had only announced on April 30 that it would report Q1 2026 results on May 13, 2026, so there is no company earnings release, no confirmed surprise versus consensus, no analyst revision wave, and no true post-print market reaction yet to evaluate [#IR-2026-04-30]. Primary-source evidence still supports a real regulatory optionality story, but the stronger current signals are the going-concern warning and Nasdaq compliance extension, which keep conviction modest [#10-K-2026-03-30] [#8-K-2026-04-02].
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-13catalystQ1 2026 results are still pending for May 13, 2026High impact
The scheduled post-earnings follow-up packet appears date-misaligned: as of May 8, 2026, the company had not yet reported Q1 2026 results and said on April 30, 2026 that it would release first-quarter 2026 financial results after market close on May 13, 2026, with the call at 4:30 PM ET [#IR-2026-04-30].
2026-09-28eventNasdaq bid-price compliance deadline remains a live overhangHigh impact
Nasdaq granted CTSO until September 28, 2026 to regain compliance with the $1.00 minimum bid requirement; 10 consecutive trading days at or above $1.00 would cure the issue, while failure keeps reverse-split or delisting risk central to the thesis [#8-K-2026-04-02].
2026-09-30catalystFDA resubmission timing and 2H 2026 cash-flow execution are the key fundamental testsHigh impact
The 10-K says CytoSorbents conducted a formal FDA pre-submission meeting in late January 2026 and remains in interactive discussions to clarify the requirements for a new DrugSorb-ATR De Novo submission, while also targeting operating cash-flow break-even in the second half of 2026; both the regulatory timetable and liquidity execution remain critical because the filing also raised substantial doubt about the company’s ability to continue as a going concern [#10-K-2026-03-30] [#IR-2026-04-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology